{"entity":{"id":"nct00884273","kind":"trial","name":"Investigation of the Effect of Degarelix in Terms of Prostate Volume Reduction in Prostate Cancer Patients","aka":[],"tldr":"A phase 3 trial of Degarelix, Goserelin / leuprolide and Bicalutamide in Prostate cancer, run by Ferring Pharmaceuticals, completed.","summary":"Investigation of the Effect of Degarelix in Terms of Prostate Volume Reduction in Prostate Cancer Patients is a phase 3 interventional study registered as NCT00884273 by Ferring Pharmaceuticals, with 182 participants recorded, started 2009-08 and reaching its primary completion in 2011-03. Interventions recorded: Degarelix, Goserelin, Bicalutamide. Conditions recorded: Prostate Cancer.\n\nLinked to the drug Degarelix because the registry names it among its interventions and Prostate cancer among its conditions. Registry record only: no result has been read by an editor.","status":"completed","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT00884273","url":"https://clinicaltrials.gov/study/NCT00884273"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["prostate"],"sections":[],"technologies":[],"targets":[],"drugs":["degarelix","goserelin","bicalutamide"],"companies":["ferring"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT00884273","phase":"3","setting":"A Randomised, Parallel-arm, Open-label Trial Comparing Degarelix With Goserelin Plus Anti-androgen Flare Protection (Bicalutamide), in Terms of Volume Reduction of the Prostate in Patients With Prostate Cancer Being Candidates for Medical Castration","sponsor":"Ferring Pharmaceuticals","started":"2009-08","yearReported":2012,"enrolled":182,"enrolledBasis":"registry","outcomes":[{"endpoint":"Change From Baseline in Prostate Size Based on Trans Rectal Ultra Sound (TRUS) at Week 12 (Full Analysis Set)","primary":true,"unit":"milliliter","arms":[{"name":"Degarelix 240 mg/80 mg","n":82,"value":-37.2,"note":"SD 16.8; Figures from the ClinicalTrials.gov results section (first posted 2012-04-11), not from a publication"},{"name":"Goserelin (3.6 mg) + Bicalutamide (50 mg)","n":97,"value":-39,"note":"SD 17.7"}],"p":"0.36","source":"https://clinicaltrials.gov/study/NCT00884273?tab=results"}]},"route":"/trials/nct00884273/","neighbours":{"cancer":[{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"drug":[{"id":"bicalutamide","kind":"drug","name":"Bicalutamide","route":"/drugs/bicalutamide/"},{"id":"degarelix","kind":"drug","name":"Degarelix","route":"/drugs/degarelix/"},{"id":"goserelin","kind":"drug","name":"Goserelin / leuprolide (ovarian function suppression)","route":"/drugs/goserelin/"}],"company":[{"id":"ferring","kind":"company","name":"Ferring Pharmaceuticals","route":"/companies/ferring/"}]}}